96 related articles for article (PubMed ID: 22825379)
1. Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer.
Gohara A; Eltaki N; Sabry D; Murtagh D; Jankun J; Selman SH; Skrzypczak-Jankun E
Oncol Rep; 2012 Oct; 28(4):1275-82. PubMed ID: 22825379
[TBL] [Abstract][Full Text] [Related]
2. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
3. 5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts.
Vincent C; Fiancette R; Donnard M; Bordessoule D; Turlure P; Trimoreau F; Denizot Y
Leuk Res; 2008 Nov; 32(11):1756-62. PubMed ID: 18561999
[TBL] [Abstract][Full Text] [Related]
4. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention.
Hoque A; Lippman SM; Wu TT; Xu Y; Liang ZD; Swisher S; Zhang H; Cao L; Ajani JA; Xu XC
Carcinogenesis; 2005 Apr; 26(4):785-91. PubMed ID: 15661803
[TBL] [Abstract][Full Text] [Related]
5. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma.
Shappell SB; Olson SJ; Hannah SE; Manning S; Roberts RL; Masumori N; Jisaka M; Boeglin WE; Vader V; Dave DS; Shook MF; Thomas TZ; Funk CD; Brash AR; Matusik RJ
Cancer Res; 2003 May; 63(9):2256-67. PubMed ID: 12727848
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
8. The rat leukocyte-type 12-lipoxygenase exhibits an intrinsic hepoxilin A3 synthase activity.
Nigam S; Patabhiraman S; Ciccoli R; Ishdorj G; Schwarz K; Petrucev B; Kühn H; Haeggström JZ
J Biol Chem; 2004 Jul; 279(28):29023-30. PubMed ID: 15123652
[TBL] [Abstract][Full Text] [Related]
9. Relationship between lipoxygenase and human testicular cancer.
Yoshimura R; Matsuyama M; Mitsuhashi M; Takemoto Y; Tsuchida K; Kawahito Y; Sano H; Nakatani T
Int J Mol Med; 2004 Mar; 13(3):389-93. PubMed ID: 14767568
[TBL] [Abstract][Full Text] [Related]
10. Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma.
Bhatnagar R; Alexiev BA
Int J Surg Pathol; 2012 Feb; 20(1):19-28. PubMed ID: 21791489
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal β-barrel domain of mammalian lipoxygenases including mouse 5-lipoxygenase is not essential for catalytic activity and membrane binding but exhibits regulatory functions.
Walther M; Hofheinz K; Vogel R; Roffeis J; Kühn H
Arch Biochem Biophys; 2011 Dec; 516(1):1-9. PubMed ID: 21951814
[TBL] [Abstract][Full Text] [Related]
12. Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival.
Guo AM; Liu X; Al-Wahab Z; Maddippati KR; Ali-Fehmi R; Scicli AG; Munkarah AR
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1273-83. PubMed ID: 21442472
[TBL] [Abstract][Full Text] [Related]
13. Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor.
Yoshimura R; Inoue K; Kawahito Y; Mitsuhashi M; Tsuchida K; Matsuyama M; Sano H; Nakatani T
Int J Mol Med; 2004 Jan; 13(1):41-6. PubMed ID: 14654968
[TBL] [Abstract][Full Text] [Related]
14. Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells.
Belfiore MC; Natoni A; Barzellotti R; Merendino N; Pessina G; Ghibelli L; Gualandi G
Cancer Lett; 2007 Sep; 254(2):236-43. PubMed ID: 17467166
[TBL] [Abstract][Full Text] [Related]
15. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.
Ding XZ; Iversen P; Cluck MW; Knezetic JA; Adrian TE
Biochem Biophys Res Commun; 1999 Jul; 261(1):218-23. PubMed ID: 10405349
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin expression in normal kidney tissue and renal carcinomas.
Dagli AF; Aydin S; Karaoglu A; Akpolat N; Ozercan IH; Ozercan MR
Pathol Res Pract; 2009; 205(3):165-73. PubMed ID: 19054628
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells.
Vermeer MA; Wilson JH; Zijlstra FJ; Vincent JE
Agents Actions; 1989 Jan; 26(1-2):252-3. PubMed ID: 2496593
[No Abstract] [Full Text] [Related]
18. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
20. Lipid metabolism: 5-lipoxygenase, 12/15-lipoxygenase, and atherogenesis.
Davidson J; Rotondo D
Curr Opin Lipidol; 2007 Feb; 18(1):107-9. PubMed ID: 17218838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
